Saxagliptin- Oral Medication Caution

The FDA wants to take another look at a pill approved in 2006 for control of glucose levels in people with type 2 diabetess. In a trial study published in the New England Journal of Medicine, saxagliptin (brand name Onglyza) was shown to coincide with an increased rate of hospitalization for heart failure of 27 percent compared to type 2s taking a placebo. The FDA has not asked prescribers and patients to stop taking saxagliptin, but to use caution while a review is underway.

Leave a Reply

Your email address will not be published. Required fields are marked *

Time limit is exhausted. Please reload CAPTCHA.